BioSpace News Archive

OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services is introducing the first and only commercially available device for in-home, self-collection of fecal samples for metabolomics.

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced that preclinical results of TNX-1700 will be presented in a poster at the American Association of Cancer Research Virtual Annual Meeting II.

Company aims to safely and effectively regenerate a healthy blood and immune system for patients with hematological malignancies, genetic diseases and autoimmune disorders

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23 at 8:30 a.m. ET.

TG Therapeutics, Inc. announced the completion of the rolling submission of a New Drug Application to the U.S. Food and Drug Administration requesting accelerated approval of umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma and follicular lymphoma.

Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced the completion of a planned sample size re-estimation of its KARE Phase 2 dose-ranging trial of Oral KORSUVA for the treatment of moderate-to-severe pruritus in atopic dermatitis patients.

Brain Scientific Inc., a neurology-focused medical device and software company, wishes to update shareholders on topics related to the commercial launch of its wholly-owned subsidiary Memory MD’s NeuroCap™, hospital-grade, disposable, preconfigured EEG headset.

Preclinical CLS-AX data demonstrates a potentially long-acting therapy for neovascular age-related macular degeneration

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, announced that the FDA has allowed an investigational new drug application to evaluate ATI-450, its oral investigational MK2 inhibitor compound, in hospitalized patients with COVID-19.

Kamada Completed Manufacturing and Released the First Batch of its Plasma-Derived Immunoglobulin Product for Coronavirus Disease (COVID-19) and it is Available for Compassionate Use Treatment in Israel; Additional Production is On-Going